TECHNOLOGY LANDSCAPE
Watch physicians and a patient discuss ways to provide the best telemedicine experience for your osteoarthritis (OA) and rheumatoid arthritis (RA) patients.
TELEMEDICINE BEST PRACTICES
Visit these online resources for additional telemedicine guidance.
OA & RA TELEMEDICINE RESOURCES
Communications to send to patients before their telemedicine visits
Attach in a communication to your patients with OA to encourage them to schedule a telemedicine visit.
Attach in a communication to your patients with RA to encourage them to schedule a telemedicine visit.
Attach in a communication to your patients to help them prepare for their telemedicine visit with your practice.
INFLAMMATION MEDICINE RESOURCES
Please see full Prescribing Information and Black Box Warning|For more Information, visit HorizonInflammationCare.com/Pennsaid
Please see full Prescribing Information and Black Box Warning|For more Information, visit HorizonInflammationCare.com/Duexis
Please see full Prescribing Information|For more Information, visit HorizonInflammationCare.com/Rayos
DOWNLOAD a guide to
help connect your patients to a Horizon medication access program
Information to show patients during their telemedicine visits
PENNSAID 2%
Communications to send to patients after their telemedicine visits
send to your patients living with chronic illness to help reinforce what was discussed and decided on during their telemedicine visit
DownloadA prescription access program pamphlet to send to your patients.
DownloadSend to your patients living with OA knee pain to help reinforce what was discussed and decided on during their telemedicine appoitment.
DownloadDOWNLOAD a guide to
help connect your patients to a Horizon medication access program
Information to show patients during their telemedicine visits
DUEXIS
A guide to use during your telemedicine visits with patients for whom you are prescribing DUEXIS.
DownloadA guide to use during your telemedicine visits with OA patients to help explain their condition.
DownloadA guide to use during your telemedicine visits with RA patients to help explain their condition.
DownloadCommunications to send to patients after their telemedicine visits
DOWNLOAD a guide to
help connect your patients to a Horizon medication access program
Information to show patients during their telemedicine visits
RAYOS
Communications to send to patients after their telemedicine visits
send to your patients living with chronic illness to help reinforce what was discussed and decided on during their telemedicine visit
DownloadA prescription access program pamphlet to send to your patients.
DownloadSend to your patients living with RA to help reinforce what was discussed and decided on during their telemedicine appointment.
DownloadDUEXIS® (ibuprofen and famotidine), a combination of the NSAID ibuprofen and the histamine H2-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) is a nonsteroidal anti-inflammatory drug indicated for the treatment of the pain of osteoarthritis of the knee(s).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
RAYOS is a corticosteroid indicated:
Please see full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
DUEXIS® (ibuprofen and famotidine), a combination of the NSAID ibuprofen and the histamine H2-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) is a nonsteroidal anti-inflammatory drug indicated for the treatment of the pain of osteoarthritis of the knee(s).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
RAYOS is a corticosteroid indicated:
Please see full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.